Glioblastoma (GBM) is the most malignant brain tumor, characterized by cell heterogeneity comprising stem cells (GSCs) responsible for aggressiveness. The calpain/calpastatin (calp/cast) proteolytic system is involved in critical physiological processes and cancer progression. In this work we showed the expression profile of hcast 3-25 (a Type III calpastatin variant devoid of inhibitory units) and the members of the system in several patient-derived GSCs exploring the relationship between hcast 3-25 and activation/activity of calpains.
View Article and Find Full Text PDFWe propose that listeners can use temporal regularities - spectro-temporal correlations that change smoothly over time - to discriminate animal vocalizations within and between species. To test this idea, we used Slow Feature Analysis (SFA) to find the most temporally regular components of vocalizations from birds (blue jay, house finch, American yellow warbler, and great blue heron), humans (English speakers), and rhesus macaques. We projected vocalizations into the learned feature space and tested intra-class (same speaker/species) and inter-class (different speakers/species) auditory discrimination by a trained classifier.
View Article and Find Full Text PDFHigh-pressure and temperature extraction (HPTE) can effectively recover bioactive compounds from olive pomace (OP). HPTE extract obtained by extracting OP with ethanol and water (50:50 /) at 180 °C for 90 min demonstrated a pronounced ability to preserve intracellular calcium homeostasis, shielding neurons from the harmful effects induced by N-methyl-d-aspartate (NMDA) receptor (NMDAR) overactivation, such as aberrant calpain activation. In this study, the extraction temperature was changed from 37 to 180 °C, and the extracts were evaluated for their antioxidant potency and ability to preserve crucial intracellular Ca-homeostasis necessary for neuronal survival.
View Article and Find Full Text PDFBackground: The most recent modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta), has been shown to improve clinical outcomes in most patients with cystic fibrosis (PwCF). Unfortunately, the clinical benefits are sometimes variable; thus, improving our knowledge of the possible causes of this variability can help reduce it.
Methods: Circulating mononuclear cells (CMCs) and plasma were collected from 16 PwCF (including those on Trikafta therapy) and 4 non-CF subjects.